Expression of NKG2D ligands by myeloid cells causes the downmodulation of NKG2D on NK cells, preventing their recognition of NKG2D ligand‐bearing tumors, and finally impairs their ability to attack and eliminate tumors, facilitates tumor immune escape (Figure 4C). Here, KLRK1 is linked to neoplasm.